Effects of synaptic modulation on β-amyloid, synaptophysin, and memory performance in Alzheimer’s disease transgenic mice


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2010
Contact PI Name:
Gunnar K. Gouras
Contact PI Affiliation:
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, USA
Co-Authors:
Davide Tampellini, Estibaliz Capetillo-Zarate, Magali Dumont, Zhenyong Huang, Fangmin Yu, Michael T. Lin
Primary Reference (PubMED ID):
Funding Source:
National Institute on Aging (NIA)
Alzheimer's Association
Zenith Fellows Award
Study Goal and Principal Findings:

Accumulation of β-amyloid (Aβ) and loss of synapses are hallmarks of Alzheimer's disease (AD). How synaptic activity relates to Aβ accumulation and loss of synapses is a current topic of major interest. Synaptic activation promotes Aβ secretion, and chronic reduction of synaptic activity reduced Aβ plaques in an AD transgenic mouse model. This suggested beneficial effects of reducing synaptic activity in AD. We now show that reduced synaptic activity causes detrimental effects on synapses and memory despite reducing plaques using two different models of chronic synaptic inhibition: deafferentation of the barrel cortex and administration of benzodiazepine. An interval of prolonged synaptic inhibition exacerbated loss of synaptophysin compared with synaptically more active brain in AD transgenic but not wild-type mice. Furthermore, an interval of benzodiazepine treatment, followed by a washout period, exacerbated memory impairment in AD transgenic mice. Exacerbation of synaptic and behavioral abnormalities occurred in the setting of reduced Aβ plaques but elevated intraneuronal Aβ immunoreactivity. These data support beneficial effects of synaptic activation on Aβ-related synaptic and behavioral impairment in AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Diazepam
Therapeutic Target:
GABA-A Receptor

Animal Model

Model Information:
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Motor Function
Swimming Speed
Histopathology
beta Amyloid Deposits
Synaptic Loss
Biochemical
Amyloid Precursor Protein (APP)
APP-CTF83 (CTF alpha)
APP-CTF99 (CTF beta)
Brain-beta Amyloid Peptide 42
Synaptophysin
Immunochemistry
Brain-beta Amyloid Deposits
Intracellular beta Amyloid Peptide 42
Cytochrome Oxidase
Postsynaptic Density Protein 95 (PSD95)
Synaptophysin
Electron Microscopy
Synapse Count
Synaptic Density

Source URL: http://alzped.nia.nih.gov/effects-synaptic-modulation-b